News Release

November 7, 2023

JCR Pharmaceuticals Co., Ltd.
Sysmex Corporation
AlliedCel Corporation
JUNTEN BIO Co., Ltd.

Translation

AlliedCel, a Joint Venture Between JCR Pharmaceuticals and Sysmex, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products

- Securing the Manufacturing and Sales License for Regenerative Medicine Products Developed by JUNTEN BIO -

JCR Pharmaceuticals Co., Ltd. (HQ: Ashiya,Hyogo,Japan; Chairman and President: Shin Ashida, hereinafter “JCR”) announces that AlliedCel Corporation (HQ: Kobe,Hyogo,Japan; President: Hiroyuki Sonoda, hereinafter “AlliedCel”), a joint venture with Sysmex Corporation (HQ: Kobe,Hyogo,Japan; President: Kaoru Asano), has entered into a license agreement with JUNTEN BIO Co., Ltd. (HQ: Chiyoda-ku, Tokyo,Japan; Representative President: Masanari Kawaminami, hereinafter “JUNTEN BIO”) to play roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101).

AlliedCel was established in October 2022 for carrying out research and development, manufacture and sales of regenerative medicine products using stem cells such as hematopoietic stem cells and other cells. In addition to the project using hematopoietic stem cell proliferation technology that AlliedCel has been promoting since its establishment, it will also move ahead on studying the possibilities of other technological developments and commercialization.

AlliedCel has recently concluded a license agreement with JUNTEN BIO to take the roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101). Inducible inhibitory T-cells (JB-101) was developed by JUNTEN BIO based on the research conducted by Juntendo University (HQ: Bunkyo-ku, Tokyo,Japan; President: Hajime Arai).

Under the supervision of Juntendo University, inducible inhibitory T-cells (JB-101) are being used

in an investigator-initiated study for living donor liver transplantation patients for the indication of suppressing immune rejection and supporting withdrawal (induction of immune tolerance) from immunosuppressants that transplant patients need to take orally continuously throughout their lives when administered to them after organ transplantation. Inducible inhibitory T-cells (JB-101) was designated under Japan's Ministry of Health, Labour and Welfare's Sakigake Designation System in 2020 as a candidate for an innovative regenerative medicine product originating from Japan and leading the world. It is scheduled for manufacturing and sales application in fiscal year 2025. Reducing the dosage of, or withdrawing, immunosuppressants is expected to not only reduce such risks as complications or infections after an organ transplant, but also to improve the survival rate of transplanted organs.

JCR and Sysmex have combined JCR's track record and know-how in developing, manufacturing, and selling regenerative medicine and other products with Sysmex's expertise in quality control testing technology and its knowledge of workflows efficiency using robotics technology, including IoT, to establish AlliedCel for R&D and early commercialization of regenerative medicine products using stem cells and other cells. The addition of Inducible inhibitory T-cells (JB-101) to AlliedCel's existing businesses will enable us to provide appropriate treatment options to patients sooner through regenerative medicine and other products.

Reference

October 3, 2022 News Release: JCR Pharmaceuticals and Sysmex Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc. - https://ssl4.eir-parts.net/doc/4552/tdnet/2186410/00.pdf

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome types A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking

statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###